{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:31:30Z","timestamp":1759743090001},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Primary central nervous system lymphoma (PCNSL) is an aggressive and rare disease. Autophagy is a catabolic mechanism boosting various tumors, including lymphomas; its inhibition is thus a promising therapeutic target. Its presence has never been studied in PCNSLs. We conducted a retrospective immunohistochemical study of 25 PCNSLs for LC3B, p62, and M6PR, comparing it with clinicopathological characteristics. Fourteen (56%) and eleven (44%) PCNSLs were of low and high LC3B expression, respectively. p62 expression was present in most tumors (n\u2009=\u200921, 84%). M6PR was present in all tumors, with 14 (56%) and 11 (44%) cases being of low and high M6PR expression, respectively. LC3B expression was correlated with the performance status (PS) (p\u2009=\u20090.04). No association was found with other clinical parameters, such as deep structure invasion, multiple lesions, complete response, and recurrence after response. p62 showed a strong positive association with MUM1 expression (p\u2009=\u20090.0005). M6PR expression showed a positive correlation (p\u2009=\u20090.04) with PD-L1 expression. No association was found with p53, Ki67, CD8, BCL2, BCL6, or double MYC\/BLC2 co-expressors. No association of LC3B, p62, and M6PR expression with survival was found. Our findings provide evidence for the possible presence of autophagic markers in PCNSLs and, thus, for possible treatment targets.<\/jats:p>","DOI":"10.1038\/s41598-021-01693-6","type":"journal-article","created":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T11:03:36Z","timestamp":1636974216000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Primary central nervous system lymphomas express immunohistochemical factors of autophagy"],"prefix":"10.1038","volume":"11","author":[{"given":"Georgia","family":"Karpathiou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia-Maria","family":"Babiuc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Camy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise","family":"Ferrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Papoudou-Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Marc","family":"Dumollard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome","family":"Cornillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Peoc\u2019h","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,15]]},"reference":[{"key":"1693_CR1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"P Kluin","year":"2017","unstructured":"Kluin, P., Deckert, M. & Ferry, J. Primary diffuse large B-cell lymphoma of the CNS. In WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (eds Swerdlow, S. H. et al.) (IARC, 2017)."},{"key":"1693_CR2","doi-asserted-by":"publisher","first-page":"5711","DOI":"10.1200\/JCO.2006.08.2941","volume":"24","author":"LE Abrey","year":"2006","unstructured":"Abrey, L. E. et al. Primary central nervous system lymphoma: The memorial Sloan-Kettering cancer center prognostic model. J. Clin. Oncol. 24, 5711\u20135715 (2006).","journal-title":"J. Clin. Oncol."},{"key":"1693_CR3","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1182\/blood-2017-02-764639","volume":"129","author":"L Alinari","year":"2017","unstructured":"Alinari, L. Toward autophagy-targeted therapy in lymphoma. Blood 129, 1740\u20131742 (2017).","journal-title":"Blood"},{"key":"1693_CR4","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s13105-020-00746-0","volume":"76","author":"MAA Al-Bari","year":"2020","unstructured":"Al-Bari, M. A. A. A current view of molecular dissection in autophagy machinery. J. Physiol. Biochem. 76, 357\u2013372 (2020).","journal-title":"J. Physiol. Biochem."},{"key":"1693_CR5","doi-asserted-by":"publisher","first-page":"39544","DOI":"10.18632\/oncotarget.9647","volume":"7","author":"AM Schl\u00e4fli","year":"2016","unstructured":"Schl\u00e4fli, A. M. et al. Prognostic value of the autophagy markers LC3 and p62\/SQSTM1 in early-stage non-small cell lung cancer. Oncotarget 7, 39544\u201339555 (2016).","journal-title":"Oncotarget"},{"key":"1693_CR6","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2020.1761742","author":"J Han","year":"2020","unstructured":"Han, J., Goldstein, L. A., Hou, W., Watkins, S. C. & Rabinowich, H. Involvement of CASP9 (caspase 9) in IGF2R\/CI-MPR endosomal transport. Autophagy https:\/\/doi.org\/10.1080\/15548627.2020.1761742 (2020).","journal-title":"Autophagy"},{"key":"1693_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/jnen\/nlab080","author":"G Karpathiou","year":"2021","unstructured":"Karpathiou, G. et al. Expression of STAT6 and phosphorylated STAT6 in primary central nervous system lymphomas. J. Neuropathol. Exp. Neurol. https:\/\/doi.org\/10.1093\/jnen\/nlab080 (2021).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"1693_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.928","volume":"8","author":"G Jahr","year":"2018","unstructured":"Jahr, G., Broi, M. D., Holte, H., Beiske, K. & Meling, T. R. Evaluation of memorial Sloan-Kettering Cancer Center and International Extranodal Lymphoma Study Group prognostic scoring systems to predict overall survival in intracranial primary CNS lymphoma. Brain Behav. 8, e00928 (2018).","journal-title":"Brain Behav."},{"key":"1693_CR9","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans, C. P. et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103, 275\u2013282 (2004).","journal-title":"Blood"},{"key":"1693_CR10","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/hon.2727","volume":"38","author":"S Hatzl","year":"2020","unstructured":"Hatzl, S. et al. Immunohistochemistry for c-myc and bcl-2 overexpression improves risk stratification in primary central nervous system lymphoma. Hematol. Oncol. 38, 277\u2013283 (2020).","journal-title":"Hematol. Oncol."},{"key":"1693_CR11","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1186\/s12885-016-2397-8","volume":"16","author":"S Kim","year":"2016","unstructured":"Kim, S. et al. MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system. BMC Cancer 16, 363 (2016).","journal-title":"BMC Cancer"},{"key":"1693_CR12","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1626653","volume":"8","author":"S Kim","year":"2019","unstructured":"Kim, S. et al. High tumoral PD-L1 expression and low PD-1 + or CD8 + tumor-infiltrating lymphocytes are predictive of a poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system. Oncoimmunology 8, e1626653 (2019).","journal-title":"Oncoimmunology"},{"key":"1693_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000597","volume":"8","author":"F Camy","year":"2020","unstructured":"Camy, F. et al. Brain metastasis PD-L1 and CD8 expression is dependent on primary tumor type and its PD-L1 and CD8 status. J. Immunother. Cancer 8, e000597 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"1693_CR14","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.3390\/cancers13092169","volume":"13","author":"G Karpathiou","year":"2021","unstructured":"Karpathiou, G. et al. Autophagic markers in chordomas: Immunohistochemical analysis and comparison with the immune microenvironment of chordoma tissues. Cancers (Basel). 13, 2169 (2021).","journal-title":"Cancers (Basel)."},{"key":"1693_CR15","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/bjc.2014.355","volume":"111","author":"J-L Liu","year":"2014","unstructured":"Liu, J.-L. et al. Prognostic significance of p62\/SQSTM1 subcellular localization and LC3B in oral squamous cell carcinoma. Br. J. Cancer 111, 944\u2013954 (2014).","journal-title":"Br. J. Cancer"},{"key":"1693_CR16","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1016\/j.ajpath.2015.05.008","volume":"185","author":"R Iwadate","year":"2015","unstructured":"Iwadate, R. et al. High expression of p62 protein is associated with poor prognosis and aggressive phenotypes in endometrial cancer. Am. J. Pathol. 185, 2523\u20132533 (2015).","journal-title":"Am. J. Pathol."},{"key":"1693_CR17","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1182\/bloodadvances.2018027672","volume":"3","author":"N Nayyar","year":"2019","unstructured":"Nayyar, N. et al. MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas. Blood Adv. 3, 375\u2013383 (2019).","journal-title":"Blood Adv."},{"key":"1693_CR18","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/j.humpath.2010.12.014","volume":"42","author":"J-J Huang","year":"2011","unstructured":"Huang, J.-J. et al. Beclin 1 expression predicts favorable clinical outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP. Hum. Pathol. 42, 1459\u20131466 (2011).","journal-title":"Hum. Pathol."},{"key":"1693_CR19","doi-asserted-by":"publisher","first-page":"777","DOI":"10.4161\/auto.6.6.12784","volume":"6","author":"J-J Huang","year":"2010","unstructured":"Huang, J.-J. et al. Beclin 1 expression: A predictor of prognosis in patients with extranodal natural killer T-cell lymphoma, nasal type. Autophagy 6, 777\u2013783 (2010).","journal-title":"Autophagy"},{"key":"1693_CR20","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/modpathol.2010.80","volume":"23","author":"G Nicotra","year":"2010","unstructured":"Nicotra, G. et al. Autophagy-active beclin-1 correlates with favourable clinical outcome in non-Hodgkin lymphomas. Mod. Pathol. 23, 937\u2013950 (2010).","journal-title":"Mod. Pathol."},{"key":"1693_CR21","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.3109\/10428194.2016.1144880","volume":"57","author":"W Willenbacher","year":"2016","unstructured":"Willenbacher, W. et al. Low Beclin-1 expression predicts improved overall survival in patients treated with immunomodulatory drugs for multiple myeloma and identifies autophagy inhibition as a promising potentially druggable new therapeutic target: An analysis from The Austrian. Leuk. Lymphoma 57, 2330\u20132341 (2016).","journal-title":"Leuk. Lymphoma"},{"key":"1693_CR22","doi-asserted-by":"publisher","first-page":"46579","DOI":"10.18632\/oncotarget.10300","volume":"7","author":"K Birkenmeier","year":"2016","unstructured":"Birkenmeier, K. et al. Basal autophagy is pivotal for Hodgkin and Reed\u2013Sternberg cells\u2019 survival and growth revealing a new strategy for Hodgkin lymphoma treatment. Oncotarget 7, 46579\u201346588 (2016).","journal-title":"Oncotarget"},{"key":"1693_CR23","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1182\/blood-2016-09-736892","volume":"129","author":"S Gayle","year":"2017","unstructured":"Gayle, S. et al. Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma. Blood 129, 1768\u20131778 (2017).","journal-title":"Blood"},{"key":"1693_CR24","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1038\/s41418-020-0496-1","volume":"27","author":"E Sanchez-Lopez","year":"2020","unstructured":"Sanchez-Lopez, E. et al. NF-\u03baB-p62-NRF2 survival signaling is associated with high ROR1 expression in chronic lymphocytic leukemia. Cell Death Differ. 27, 2206\u20132216 (2020).","journal-title":"Cell Death Differ."},{"key":"1693_CR25","doi-asserted-by":"publisher","first-page":"6410","DOI":"10.1158\/0008-5472.CAN-16-0595","volume":"76","author":"H Zhang","year":"2016","unstructured":"Zhang, H., Chen, Z., Miranda, R. N., Medeiros, L. J. & McCarty, N. TG2 and NF-\u03baB signaling coordinates the survival of mantle cell lymphoma cells via IL6-mediated autophagy. Cancer Res. 76, 6410\u20136423 (2016).","journal-title":"Cancer Res."},{"key":"1693_CR26","doi-asserted-by":"publisher","first-page":"265","DOI":"10.4161\/auto.8.2.18763","volume":"8","author":"TG Sommermann","year":"2012","unstructured":"Sommermann, T. G., Mack, H. I. D. & Cahir-McFarland, E. Autophagy prolongs survival after NF\u03baB inhibition in B-cell lymphomas. Autophagy 8, 265\u2013267 (2012).","journal-title":"Autophagy"},{"key":"1693_CR27","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1111\/bjh.12440","volume":"162","author":"C Bertolo","year":"2013","unstructured":"Bertolo, C. et al. LITAF, a BCL6 target gene, regulates autophagy in mature B-cell lymphomas. Br. J. Haematol. 162, 621\u2013630 (2013).","journal-title":"Br. J. Haematol."},{"key":"1693_CR28","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41586-020-2545-9","volume":"584","author":"SM Banik","year":"2020","unstructured":"Banik, S. M. et al. Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature 584, 291\u2013297 (2020).","journal-title":"Nature"},{"key":"1693_CR29","doi-asserted-by":"publisher","first-page":"5483","DOI":"10.1158\/0008-5472.CAN-12-2236","volume":"72","author":"R Ramakrishnan","year":"2012","unstructured":"Ramakrishnan, R. et al. Autophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy. Cancer Res. 72, 5483\u20135493 (2012).","journal-title":"Cancer Res."},{"key":"1693_CR30","doi-asserted-by":"publisher","first-page":"615","DOI":"10.4161\/auto.23485","volume":"9","author":"R Ramakrishnan","year":"2013","unstructured":"Ramakrishnan, R. & Gabrilovich, D. I. The role of mannose-6-phosphate receptor and autophagy in influencing the outcome of combination therapy. Autophagy 9, 615\u2013616 (2013).","journal-title":"Autophagy"},{"key":"1693_CR31","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1007\/s00262-018-2199-8","volume":"67","author":"J Wahba","year":"2018","unstructured":"Wahba, J. et al. Chemotherapy-induced apoptosis, autophagy and cell cycle arrest are key drivers of synergy in chemo-immunotherapy of epithelial ovarian cancer. Cancer Immunol. Immunother. 67, 1753\u20131765 (2018).","journal-title":"Cancer Immunol. Immunother."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-01693-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-01693-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-01693-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T17:33:11Z","timestamp":1670088791000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-01693-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,15]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["1693"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-01693-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,15]]},"assertion":[{"value":"13 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22259"}}